Ching Sung Hsu
Vorsitzender bei Formosa Lithium Iron Oxide Corp.
Profil
Ching Sung Hsu is currently the Chairman at Formosa Lithium Iron Oxide Corp.
Prior to this, he held the position of Vice Chairman at United BioPharma, Inc. and UBI Pharma Inc. He also served as a Director at Changs Ascending Enterprise Co., Ltd.
and Taiwan Leader Biotech Corp.
where he held the position of Director from 2009 to 2017.
Mr. Hsu completed his undergraduate degree from Feng Chia University.
Aktive Positionen von Ching Sung Hsu
| Unternehmen | Position | Beginn |
|---|---|---|
| Formosa Lithium Iron Oxide Corp. | Vorsitzender | - |
Ehemalige bekannte Positionen von Ching Sung Hsu
| Unternehmen | Position | Ende |
|---|---|---|
| TAIWAN LEADER BIOTECH CORP. | Direktor/Vorstandsmitglied | 30.03.2017 |
| UBI PHARMA INC. | Direktor/Vorstandsmitglied | - |
| UNITED BIOPHARMA INC | Direktor/Vorstandsmitglied | - |
| CHANGS ASCENDING ENTERPRISE CO., LTD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Ching Sung Hsu
| Feng Chia University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CHANGS ASCENDING ENTERPRISE CO., LTD. | Producer Manufacturing |
| TAIWAN LEADER BIOTECH CORP. | Health Technology |
| UBI PHARMA INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Formosa Lithium Iron Oxide Corp. | |
United BioPharma, Inc.
 United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |
